語系:
繁體中文
English
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Treatment of cystic fibrosis and oth...
~
Azuma, Arata.
Treatment of cystic fibrosis and other rare lung diseases
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
Treatment of cystic fibrosis and other rare lung diseases/ edited by Arata Azuma, Michael S. Schechter.
其他作者:
Azuma, Arata.
出版者:
Basel :Springer Basel : : 2017.,
面頁冊數:
viii, 263 p. :ill., digital ; : 24 cm.;
Contained By:
Springer eBooks
標題:
Cystic fibrosis - Treatment. -
電子資源:
http://dx.doi.org/10.1007/978-3-0348-0977-1
ISBN:
9783034809771
Treatment of cystic fibrosis and other rare lung diseases
Treatment of cystic fibrosis and other rare lung diseases
[electronic resource] /edited by Arata Azuma, Michael S. Schechter. - Basel :Springer Basel :2017. - viii, 263 p. :ill., digital ;24 cm. - Milestones in drug therapy,2296-6056. - Milestones in drug therapy..
Part I Etiopathology and Genetics of Rare Lung Diseases -- Part II Treatment of Cystic Fibrosis -- Part III Treatment of Other Rare Lung Diseases.
This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions. It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.
ISBN: 9783034809771
Standard No.: 10.1007/978-3-0348-0977-1doiSubjects--Topical Terms:
1069997
Cystic fibrosis
--Treatment.
LC Class. No.: RC858.C95
Dewey Class. No.: 616.372
Treatment of cystic fibrosis and other rare lung diseases
LDR
:02199nam a2200325 a 4500
001
958667
003
DE-He213
005
20170201181627.0
006
m d
007
cr nn 008maaau
008
201118s2017 sz s 0 eng d
020
$a
9783034809771
$q
(electronic bk.)
020
$a
9783034809757
$q
(paper)
024
7
$a
10.1007/978-3-0348-0977-1
$2
doi
035
$a
978-3-0348-0977-1
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
RC858.C95
072
7
$a
MMG
$2
bicssc
072
7
$a
MED071000
$2
bisacsh
082
0 4
$a
616.372
$2
23
090
$a
RC858.C95
$b
T784 2017
245
0 0
$a
Treatment of cystic fibrosis and other rare lung diseases
$h
[electronic resource] /
$c
edited by Arata Azuma, Michael S. Schechter.
260
$a
Basel :
$c
2017.
$b
Springer Basel :
$b
Imprint: Springer,
300
$a
viii, 263 p. :
$b
ill., digital ;
$c
24 cm.
490
1
$a
Milestones in drug therapy,
$x
2296-6056
505
0
$a
Part I Etiopathology and Genetics of Rare Lung Diseases -- Part II Treatment of Cystic Fibrosis -- Part III Treatment of Other Rare Lung Diseases.
520
$a
This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions. It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.
650
0
$a
Cystic fibrosis
$x
Treatment.
$3
1069997
650
0
$a
Lungs
$x
Diseases
$x
Treatment.
$3
970020
650
1 4
$a
Biomedicine.
$3
593880
650
2 4
$a
Pharmacology/Toxicology.
$3
593882
650
2 4
$a
Pneumology/Respiratory System.
$3
668561
650
2 4
$a
Internal Medicine.
$3
668583
650
2 4
$a
Immunology.
$3
592892
700
1
$a
Azuma, Arata.
$3
1250984
700
1
$a
Schechter, Michael S.
$3
1250985
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer eBooks
830
0
$a
Milestones in drug therapy.
$3
887606
856
4 0
$u
http://dx.doi.org/10.1007/978-3-0348-0977-1
950
$a
Biomedical and Life Sciences (Springer-11642)
筆 0 讀者評論
多媒體
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼[密碼必須為2種組合(英文和數字)及長度為10碼以上]
登入